Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Evorpacept by ALX Oncology for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According...
Evorpacept by ALX Oncology for Gastric Cancer: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase III for Gastric Cancer. According to GlobalData, Phase...
Evorpacept by ALX Oncology for Endometrial Cancer: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Evorpacept by ALX Oncology for Epithelial Ovarian Cancer: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Evorpacept by ALX Oncology for Oropharyngeal Cancer: Likelihood of Approval
Evorpacept is under clinical development by ALX Oncology and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of ALX Oncology's Evorpacept?
Evorpacept is a fusion protein commercialized by ALX Oncology, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal...